Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other financing activities (2016 - 2018)

Aptevo Therapeutics' Other financing activities history spans 3 years, with the latest figure at $601000.0 for Q3 2018.

  • For Q3 2018, Other financing activities rose 191.2% year-over-year to $601000.0; the TTM value through Sep 2018 reached -$10.2 million, down 506.21%, while the annual FY2017 figure was -$10.0 million, 609.68% down from the prior year.
  • Other financing activities for Q3 2018 was $601000.0 at Aptevo Therapeutics, up from -$10.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.4 million in Q4 2016 and bottomed at -$10.2 million in Q4 2017.
  • The 3-year median for Other financing activities is $302500.0 (2017), against an average of -$1.2 million.
  • The largest annual shift saw Other financing activities tumbled 529.72% in 2017 before it surged 191.2% in 2018.
  • A 3-year view of Other financing activities shows it stood at $2.4 million in 2016, then crashed by 529.72% to -$10.2 million in 2017, then skyrocketed by 105.92% to $601000.0 in 2018.
  • Per Business Quant, the three most recent readings for APVO's Other financing activities are $601000.0 (Q3 2018), -$10.2 million (Q4 2017), and -$659000.0 (Q3 2017).